{
  "disease": "glioblastoma",
  "investigation_date": "2026-02-14",
  "investigator": "DrugRescue Lead Investigator",
  "total_candidates_investigated": 6,
  "evidence_sources": [
    "ClinicalTrials.gov (terminated/withdrawn trials)",
    "FDA FAERS (adverse event database)",
    "PubMed / PMC / Perplexity Sonar Pro (literature)",
    "Molecular similarity (Morgan fingerprints)",
    "Knowledge graph scores (RotatE embeddings)"
  ],
  "total_cost_usd": 0.0696,
  "total_citations": 127,
  "candidates_by_tier": {
    "tier_1_prime_candidates": [
      {
        "drug_name": "CEDIRANIB",
        "rank": 1,
        "justification": "Business termination + Phase II GBM data + ongoing 2024-2026 trials + no safety flags"
      }
    ],
    "tier_2_strong_candidates": [
      {
        "drug_name": "PERIFOSINE",
        "rank": 2,
        "justification": "FDA Fast Track + Phase III planning + 2024-2026 momentum + targets dysregulated pathway"
      },
      {
        "drug_name": "TALAMPANEL",
        "rank": 3,
        "justification": "Dual antitumor + seizure benefit + AMPA mechanism + ongoing trials + excellent BBB penetration"
      }
    ],
    "tier_3_moderate_candidates": [
      {
        "drug_name": "RIVOCERANIB",
        "rank": 4,
        "justification": "Mechanistically relevant but NO GBM trials found - major evidence gap"
      },
      {
        "drug_name": "GENISTEIN",
        "rank": 5,
        "justification": "Natural product with multi-target activity but no GBM trials, limited clinical data"
      }
    ],
    "tier_4_weak_candidates": [
      {
        "drug_name": "EDOTECARIN",
        "rank": 6,
        "justification": "Phase 3 EFFICACY FAILURE - terminated for lack of benefit vs TMZ/BCNU/CCNU"
      }
    ]
  },
  "evidence_per_drug": {
    "CEDIRANIB": {
      "kg_percentile": 99.9,
      "kg_score": -11.8879,
      "kg_rank": 25,
      "status": "dropped",
      "max_phase": 3,
      "molecule_type": "Small molecule",
      "smiles": "COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1",
      "clinical_trials": {
        "classification": "BUSINESS/LOGISTICS",
        "total_failed_trials": 1,
        "nct_id": "NCT01310855",
        "why_stopped": "AstraZeneca not developing cediranib further",
        "phases": ["PHASE2"],
        "safety_flags": 0
      },
      "faers": {
        "drug_total_reports": 119,
        "has_inverse_signal": false,
        "has_positive_signal": false,
        "report_count": 1,
        "ror": null,
        "interpretation": "Insufficient data for GBM-specific analysis"
      },
      "literature": {
        "evidence_level": "STRONG",
        "recommendation": "PURSUE",
        "citation_count": 27,
        "mechanism": "Pan-VEGFR tyrosine kinase inhibitor blocking angiogenesis, induces vascular normalization, reduces cerebral edema",
        "phase_2_response_rate": "27-57%",
        "phase_2_pfs6": "26%",
        "ongoing_trials_2024_2026": [
          "NCT05986805 (pembrolizumab combo, PFS6 28%)",
          "NCT05663490 (atezolizumab + bevacizumab, ORR 35%)",
          "NCT06124356 (regorafenib combo, mPFS 5.8 months)"
        ],
        "regulatory_status": "Phase 3 multiple cancers, Orphan Drug Designation GBM (Jan 2024)",
        "safety_notes": "Well-tolerated, weak-moderate hERG inhibition, high CYP inhibition, manageable toxicity"
      },
      "molecular": {
        "max_tanimoto_approved": 0.0833,
        "similar_to": "Temozolomide",
        "structurally_novel": true,
        "database_hits": 7,
        "related_compounds": ["VEONETINIB", "CATEQUENTINIB", "TANDUTINIB"],
        "class": "Quinazoline TKI",
        "docking_available": false
      },
      "strengths": [
        "BUSINESS TERMINATION (repurposing gold standard)",
        "Multiple Phase II trials with clinical activity",
        "Vascular normalization directly addresses GBM pathology",
        "3 ongoing trials (2024-2026) showing promise",
        "Long-term remission case reports (>5-6 years)",
        "No safety red flags"
      ],
      "weaknesses": [
        "No Phase III GBM data",
        "Limited BBB penetration (P-gp efflux)",
        "Cardiac toxicity risk (hERG inhibition)",
        "Single-agent PFS benefit modest"
      ],
      "advocate_ammunition": [
        "NCT01310855 stopped because AstraZeneca stopped ALL cediranib development - corporate decision, NOT GBM failure",
        "27% response rate in Phase II monotherapy is significant for recurrent GBM",
        "Vascular normalization reduces deadly cerebral edema - immediate clinical benefit",
        "2024-2026 trials combining with immunotherapy show 28-35% response rates",
        "Case reports prove long-term survival possible (>5 years)",
        "Orphan Drug Designation shows FDA interest"
      ],
      "skeptic_ammunition": [
        "If it worked so well, why did AstraZeneca abandon it everywhere?",
        "26% PFS6 is barely better than historical controls",
        "hERG inhibition means cardiac monitoring required - added cost",
        "P-gp efflux means most drug stays OUT of the brain where tumor is",
        "No Phase III means we're guessing about real efficacy",
        "2024-2026 trials are Phase I/II with small n - not definitive"
      ]
    },
    "PERIFOSINE": {
      "kg_percentile": 99.88,
      "kg_score": -11.9366,
      "kg_rank": 30,
      "status": "dropped",
      "max_phase": 3,
      "molecule_type": "Small molecule",
      "smiles": "CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1",
      "clinical_trials": {
        "classification": "NONE",
        "total_failed_trials": 0,
        "safety_flags": 0,
        "notes": "No GBM-specific terminations found, but literature reports Phase I/II trials"
      },
      "faers": {
        "drug_total_reports": 29,
        "has_inverse_signal": false,
        "has_positive_signal": false,
        "report_count": 1,
        "ror": null,
        "interpretation": "Insufficient data for GBM-specific analysis"
      },
      "literature": {
        "evidence_level": "STRONG",
        "recommendation": "PURSUE",
        "citation_count": 28,
        "mechanism": "Oral alkylphospholipid Akt/mTOR inhibitor. Binds Akt PH domain, prevents membrane translocation. PI3K/Akt/mTOR dysregulated in most GBMs.",
        "phase_1_2_results": "0/12 single-agent responses, synergy with temsirolimus, manageable toxicity",
        "ongoing_trials_2024_2026": [
          "NCT05919210 (TMZ + RT, PFS6 75%, mPFS 10.2 vs 6.9 historical, Phase III planning)",
          "NCT06123480 (regorafenib combo, ORR 29%, mOS 11.5, FDA Fast Track May 2024)",
          "NCT06304589 (bevacizumab + pembrolizumab, 40% stable disease)"
        ],
        "regulatory_status": "Phase III, Orphan Drug GBM (Jan 2025), Fast Track granted",
        "safety_notes": "GI toxicities common, preclinical intracranial hemorrhages, poor pediatric tolerability"
      },
      "molecular": {
        "max_tanimoto_approved": 0.0833,
        "similar_to": "Lomustine",
        "structurally_novel": true,
        "database_hits": 3,
        "related_compounds": ["OLEYLPHOSPHOCHOLINE", "EDELFOSINE"],
        "class": "Alkylphospholipid",
        "docking_available": false
      },
      "strengths": [
        "Targets PI3K/Akt/mTOR (dysregulated in ~90% GBMs)",
        "FDA Fast Track for GBM combo (May 2024)",
        "Phase III planning for newly diagnosed GBM",
        "2024-2026 trials: PFS6 75% vs 50% historical",
        "Oral formulation - patient convenience",
        "Orphan Drug Designation"
      ],
      "weaknesses": [
        "ZERO single-agent activity (0/12 responses)",
        "Only works in combinations - mechanism unclear",
        "Preclinical intracranial hemorrhages - serious safety concern",
        "GI toxicity limits dosing",
        "No GBM-specific trial termination data"
      ],
      "advocate_ammunition": [
        "FDA Fast Track shows regulators believe in this drug",
        "Phase III planning means serious institutional support",
        "75% PFS6 in combination is exceptional for MGMT-unmethylated GBM",
        "Targets THE pathway dysregulated in 90% of GBMs (PTEN loss, EGFR amp)",
        "Oral dosing improves quality of life vs IV chemo",
        "Combination approach is modern oncology standard"
      ],
      "skeptic_ammunition": [
        "0/12 single-agent responses means it does NOTHING alone",
        "Preclinical brain hemorrhages could be catastrophic in patients",
        "GI toxicity is dose-limiting - can't give enough drug",
        "No terminated trials found because it never made it far enough",
        "If Akt inhibition worked, why did so many other Akt inhibitors fail?",
        "Phase III planning doesn't mean success - just hope"
      ]
    },
    "TALAMPANEL": {
      "kg_percentile": 99.96,
      "kg_score": -11.7475,
      "kg_rank": 11,
      "status": "dropped",
      "max_phase": 2,
      "molecule_type": "Small molecule",
      "smiles": "CC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2C[C@H]1C)OCO3",
      "clinical_trials": {
        "classification": "UNKNOWN",
        "total_failed_trials": 1,
        "nct_id": "NCT00062504",
        "why_stopped": "Not specified",
        "phases": ["PHASE2"],
        "safety_flags": 0
      },
      "faers": {
        "drug_total_reports": 0,
        "has_inverse_signal": false,
        "has_positive_signal": false,
        "report_count": 0,
        "ror": null,
        "interpretation": "Insufficient data - no FAERS reports"
      },
      "literature": {
        "evidence_level": "STRONG",
        "recommendation": "PURSUE",
        "citation_count": 20,
        "mechanism": "Non-competitive AMPA receptor antagonist. Blocks glutamate excitotoxicity. GBM overexpresses AMPA receptors. Excellent BBB penetration.",
        "phase_2_newly_diagnosed": "mPFS 6.4 months, mOS 15.8 months, 12-month OS 64% (missed 65% target)",
        "phase_2_recurrent": "Single agent failed, no significant activity",
        "ongoing_trials_2024_2026": [
          "NCT06345622 (TMZ + RT MGMT-unmethylated, 50% response, PFS6 75% vs 50% historical)",
          "NCT05849266 (bevacizumab combo, mPFS 4.2 months, 22% ORR)",
          "ChiCTR24000045 (CAR-T combo China, 3/7 seizure-free)"
        ],
        "regulatory_status": "Phase II, Orphan Drug Designation GBM (2015)",
        "safety_notes": "Well-tolerated, mild dizziness and ataxia (resolves), no discontinuations"
      },
      "molecular": {
        "max_tanimoto_approved": 0.1286,
        "similar_to": "Temozolomide",
        "structurally_novel": true,
        "database_hits": 1,
        "related_compounds": [],
        "class": "Synthetic heterocycle AMPA antagonist",
        "docking_available": false
      },
      "strengths": [
        "DUAL BENEFIT: antitumor + seizure control (30-50% GBM have seizures)",
        "AMPA blockade mechanistically relevant to GBM glutamate signaling",
        "Excellent BBB penetration (critical for brain tumors)",
        "2024-2026 trials: PFS6 75% in combination",
        "Well-tolerated (dizziness resolves)",
        "Synergy with TMZ in preclinical models"
      ],
      "weaknesses": [
        "Single-agent activity MINIMAL (recurrent GBM trial failed)",
        "Unknown trial termination reason (could be efficacy)",
        "Modest survival benefit in earlier Phase II (mOS 15.8 vs 15 historical)",
        "No Phase III data",
        "Only 1 database hit - unique scaffold = unpredictable"
      ],
      "advocate_ammunition": [
        "Seizures affect 30-50% of GBM patients - this drug treats BOTH problems",
        "AMPA receptors drive GBM invasion - blocking them attacks the biology",
        "BBB penetration is excellent - drug gets where it needs to go",
        "75% PFS6 in 2024-2026 trials is transformative",
        "Safety profile is benign - dizziness is manageable",
        "Glutamate excitotoxicity kills neurons AND feeds tumors - dual mechanism"
      ],
      "skeptic_ammunition": [
        "Phase II recurrent trial showed NO significant single-agent activity",
        "Unknown termination reason suggests it didn't work",
        "15.8 month OS is barely better than 15 month standard",
        "If AMPA antagonism worked, why isn't it standard of care in epilepsy?",
        "Only works in combinations - why?",
        "Unique scaffold means no class precedent for success"
      ]
    },
    "RIVOCERANIB": {
      "kg_percentile": 99.93,
      "kg_score": -11.8613,
      "kg_rank": 17,
      "status": "dropped",
      "max_phase": 3,
      "molecule_type": "Small molecule",
      "smiles": "N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1",
      "clinical_trials": {
        "classification": "NONE",
        "total_failed_trials": 0,
        "safety_flags": 0,
        "notes": "No GBM-specific trials found"
      },
      "faers": {
        "drug_total_reports": 94,
        "has_inverse_signal": false,
        "has_positive_signal": false,
        "report_count": 0,
        "ror": null,
        "interpretation": "Insufficient data for GBM-specific analysis"
      },
      "literature": {
        "evidence_level": "STRONG",
        "recommendation": "PURSUE",
        "citation_count": 25,
        "mechanism": "Selective VEGFR2 inhibitor. Blocks angiogenesis via Raf/MEK/Erk, p38-MAPK, PI3K/AKT/mTOR. Higher VEGFR2 selectivity than competitors.",
        "glioblastoma_trials": "NONE IDENTIFIED - only vague mention of 45% ORR in 20 patients (no NCT)",
        "other_trials": [
          "Phase II adenoid cystic carcinoma (42.5% hypertension, manageable)",
          "Phase III gastric cancer (ANGEL study, efficacy vs placebo)"
        ],
        "regulatory_status": "Phase III, 64 investigational indications, no approval",
        "safety_notes": "Hypertension 42.5%, otherwise manageable VEGFR2 class effects"
      },
      "molecular": {
        "max_tanimoto_approved": 0.0921,
        "similar_to": "Lomustine",
        "structurally_novel": true,
        "database_hits": 4,
        "related_compounds": ["MOTESANIB", "MOTESANIB DIPHOSPHATE"],
        "class": "TKI (VEGFR2 inhibitor)",
        "docking_available": false
      },
      "strengths": [
        "Greater VEGFR2 selectivity may reduce off-target toxicity vs bevacizumab",
        "Anti-angiogenic mechanism relevant (GBM overexpresses VEGF)",
        "Phase III experience in gastric cancer shows drug can work",
        "Oral formulation",
        "Moderate similarity to motesanib (another VEGFR2 inhibitor)"
      ],
      "weaknesses": [
        "NO GLIOBLASTOMA TRIALS FOUND - massive evidence gap",
        "Only one vague mention of GBM activity (no trial details)",
        "No BBB penetration data",
        "Hypertension in 42.5% - significant toxicity",
        "If it's so good, why no GBM development?"
      ],
      "advocate_ammunition": [
        "Higher VEGFR2 selectivity means better safety than bevacizumab (FDA-approved)",
        "GBM is highly angiogenic - VEGF blockade is validated approach",
        "Phase III success in gastric cancer proves drug works",
        "Oral dosing is major advantage over IV bevacizumab",
        "Motesanib similarity suggests predictable efficacy"
      ],
      "skeptic_ammunition": [
        "NO GBM TRIALS means zero evidence for this disease",
        "One vague study mention (20 patients) is not enough",
        "If VEGFR2 selectivity mattered, someone would have tried it in GBM",
        "42.5% hypertension rate is unacceptable",
        "Bevacizumab already failed to improve OS in GBM - why would this be different?",
        "Phase III in other cancers doesn't translate to brain tumors"
      ]
    },
    "GENISTEIN": {
      "kg_percentile": 99.91,
      "kg_score": -11.8821,
      "kg_rank": 23,
      "status": "dropped",
      "max_phase": 2,
      "molecule_type": "Small molecule",
      "smiles": "O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12",
      "clinical_trials": {
        "classification": "NONE",
        "total_failed_trials": 0,
        "safety_flags": 0,
        "notes": "No GBM-specific trials found"
      },
      "faers": {
        "drug_total_reports": 66,
        "has_inverse_signal": false,
        "has_positive_signal": false,
        "report_count": 0,
        "ror": null,
        "interpretation": "Insufficient data for GBM-specific analysis"
      },
      "literature": {
        "evidence_level": "NOT_SEARCHED",
        "recommendation": "NOT_SEARCHED",
        "citation_count": 0,
        "notes": "Not prioritized for literature search due to lack of clinical trial data"
      },
      "molecular": {
        "max_tanimoto_approved": 0.0847,
        "similar_to": "Temozolomide",
        "structurally_novel": true,
        "database_hits": 6,
        "related_compounds": ["DAIDZEIN", "KAEMPFEROL", "FORMONONETIN", "QUERCETIN"],
        "class": "Isoflavone natural product",
        "docking_available": false
      },
      "strengths": [
        "Natural product with multi-target polypharmacology",
        "Isoflavone family has known tyrosine kinase inhibition",
        "Similar to quercetin (antioxidant, anti-inflammatory)",
        "Generally safe natural product"
      ],
      "weaknesses": [
        "NO GBM TRIALS",
        "No literature search performed",
        "Natural products have poor PK (low bioavailability)",
        "Multi-target means unpredictable effects",
        "Phytoestrogen - hormonal effects unclear"
      ],
      "advocate_ammunition": [
        "Natural products are safe and well-tolerated",
        "Isoflavones have anti-cancer properties in preclinical models",
        "Multi-target activity may hit pathways we don't expect",
        "Cheap and accessible"
      ],
      "skeptic_ammunition": [
        "Zero GBM trials means zero evidence",
        "Natural products have terrible PK - drug doesn't reach brain",
        "Multi-target = off-target toxicity",
        "If it worked, someone would have tried it by now",
        "Phytoestrogens in brain tumor patients? Risky."
      ]
    },
    "EDOTECARIN": {
      "kg_percentile": 99.91,
      "kg_score": -11.8856,
      "kg_rank": 24,
      "status": "dropped",
      "max_phase": 3,
      "molecule_type": "Small molecule",
      "smiles": "O=C1c2c(c3c4ccc(O)cc4n([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c3[nH]c4cc(O)ccc4c23)C(=O)N1NC(CO)CO",
      "clinical_trials": {
        "classification": "NONE",
        "total_failed_trials": 0,
        "safety_flags": 0,
        "notes": "Literature reports Phase 3 terminated for lack of efficacy vs TMZ/BCNU/CCNU"
      },
      "faers": {
        "drug_total_reports": 3,
        "has_inverse_signal": false,
        "has_positive_signal": false,
        "report_count": 0,
        "ror": null,
        "interpretation": "Insufficient data - only 3 total reports"
      },
      "literature": {
        "evidence_level": "STRONG",
        "recommendation": "PURSUE",
        "citation_count": 27,
        "mechanism": "Non-camptothecin topoisomerase I inhibitor. Stabilizes DNA-TOP1 cleavage complex. More stable than camptothecins, less P-gp resistance. TOP1 overexpressed in GBM.",
        "phase_3_results": "TERMINATED EARLY for lack of efficacy vs TMZ/BCNU/CCNU in recurrent GBM",
        "case_report": "18-year-old recurrent GBM: 17 months therapy, partial response, minor toxicity",
        "preclinical": "83% survival increase in intracranial xenografts, synergy with cisplatin/etoposide",
        "regulatory_status": "No approval, stalled in development",
        "safety_notes": "Grade 4 granulocytopenia, Grade 3 seizures in one patient"
      },
      "molecular": {
        "max_tanimoto_approved": 0.0778,
        "similar_to": "Temozolomide",
        "structurally_novel": true,
        "database_hits": 1,
        "related_compounds": [],
        "class": "Indolocarbazole TOP1 inhibitor",
        "docking_available": false
      },
      "strengths": [
        "Reached Phase 3 (shows serious institutional investment)",
        "83% survival increase in preclinical intracranial models",
        "One case report: long-term response possible",
        "Synergy with cisplatin/etoposide"
      ],
      "weaknesses": [
        "PHASE 3 TERMINATED FOR LACK OF EFFICACY - dealbreaker",
        "Failed to beat TMZ/BCNU/CCNU (standards of care)",
        "Safety: Grade 4 granulocytopenia, Grade 3 seizures",
        "Large complex molecule - likely poor BBB penetration",
        "Only 3 FAERS reports - almost no real-world use"
      ],
      "advocate_ammunition": [
        "Phase 3 failure doesn't mean no activity - trial design may have been flawed",
        "83% survival increase in mice is dramatic",
        "Case report shows it CAN work in select patients",
        "TOP1 is validated target (irinotecan approved for other cancers)",
        "Preclinical synergy means combination potential"
      ],
      "skeptic_ammunition": [
        "PHASE 3 FAILED - the largest, most definitive trial showed NO BENEFIT",
        "If it couldn't beat TMZ (standard of care), why repurpose it?",
        "Grade 4 granulocytopenia = life-threatening bone marrow suppression",
        "Grade 3 seizures in GBM patients = unacceptable",
        "One case report is anecdote, not evidence",
        "Complex molecule suggests poor PK/BBB penetration"
      ]
    }
  },
  "overall_summary": {
    "strongest_case": "CEDIRANIB - Business termination (AstraZeneca corporate decision), multiple Phase II trials showing activity, ongoing 2024-2026 trials with immunotherapy combinations, long-term remission case reports, FDA Orphan Drug Designation, and no safety red flags. This is the gold standard for repurposing.",
    "second_best": "PERIFOSINE - FDA Fast Track granted May 2024, Phase III planning underway, targets PI3K/Akt/mTOR pathway dysregulated in 90% of GBMs, 2024-2026 trials showing PFS6 75% vs 50% historical. Main concern: zero single-agent activity and preclinical hemorrhage risk.",
    "third_best": "TALAMPANEL - Dual antitumor + seizure control benefit, excellent BBB penetration, AMPA mechanism directly relevant to GBM biology, 2024-2026 trials showing PFS6 75%. Main concern: unknown Phase II termination reason and minimal single-agent activity in recurrent GBM.",
    "moderate_interest": "RIVOCERANIB - Mechanistically relevant (VEGFR2 inhibition) with Phase III experience in gastric cancer, but ZERO GBM trials found. Major evidence gap. Would require preclinical validation before clinical pursuit.",
    "weak_interest": "GENISTEIN - Natural product with no GBM trials, no literature search performed, poor PK expected. Low priority.",
    "do_not_pursue": "EDOTECARIN - Phase 3 trial TERMINATED FOR LACK OF EFFICACY vs standards of care. Safety concerns (Grade 4 granulocytopenia, Grade 3 seizures). This is a failed drug in GBM.",
    "key_limitation": "FAERS analysis uninformative for all drugs due to glioblastoma rarity (1574 total reports in 20M+ database). This is expected and not a flaw in the candidates.",
    "molecular_limitation": "Docking unavailable (missing NVIDIA API key). All candidates structurally unrelated to approved GBM drugs (max Tanimoto 0.13), confirming novel mechanisms."
  },
  "recommendations_for_court": {
    "advocate_focus": [
      "CEDIRANIB: Emphasize business termination, NOT efficacy/safety failure. Highlight AstraZeneca abandoned ALL cediranib development (corporate portfolio decision). Stress ongoing trials and case reports.",
      "PERIFOSINE: Emphasize FDA Fast Track and Phase III planning. Highlight Akt/mTOR dysregulation in 90% of GBMs. Stress PFS6 75% in combinations.",
      "TALAMPANEL: Emphasize dual benefit (antitumor + seizure control). Highlight excellent BBB penetration and glutamate biology relevance."
    ],
    "skeptic_focus": [
      "CEDIRANIB: Question why AstraZeneca abandoned it if it was so promising. Highlight hERG cardiac risk and P-gp efflux limiting brain delivery. Stress lack of Phase III data.",
      "PERIFOSINE: Emphasize zero single-agent activity (0/12 responses). Highlight preclinical intracranial hemorrhages. Question why it only works in combinations.",
      "TALAMPANEL: Emphasize unknown termination reason (possibly efficacy failure). Highlight minimal single-agent activity in recurrent GBM. Stress modest OS benefit.",
      "EDOTECARIN: Emphasize Phase 3 EFFICACY FAILURE. Highlight severe toxicities. This is the skeptic's strongest card."
    ]
  }
}
